Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have ...

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (NYSE:HIMS), an estimated $18.07 million trade based on quarterly average pricing.

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is building a consumer-first digital health platform aimed at expanding access to personalized, ongoing care through a ...

After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health (NYSE: HIMS) is making headlines as shares are surging in the wake of an agreement with GLP-1 maker ...

The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' ...

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped 3%. Bank of America upgraded the stock to neutral from underperform after ...

As the Super Bowl approached halftime, Hims & Hers publicly staked its claim to preventive medicine in front of the American people. In a one-minute ad, the direct-to-consumer health company ...

After years of fighting over compounded weight loss drugs, Hims & Hers and Novo Nordisk are teaming up to sell Ozempic and Wegovy — a shift that could raise costs for patients.

Hims & Hers received a flurry of upgrades, though most analysts are opting to stay on the sidelines. Here’s why.

Hims stock surged more than 40% Monday morning on news that Novo Nordisk will distribute its weight loss drugs through the Hims platform.

Hims & Hers (HIMS) jumped 34.47% past week to $22.16, targets $23-$28. Teladoc Health (TDOC) at $5.30, Deutsche Bank target $11. Alector (ALEC) up 40.38% YTD to $2.19, BTIG target $6. Analysts ...